195053-92-0

Usage

Uses

Used in Chemical Research:
2-(1-Trityl-1H-imidazol-4-yl)-ethylamine hydrate is used as a research compound for exploring its chemical properties and potential applications in various fields. Its unique combination of trityl, imidazole, and ethylamine groups may offer novel reactivity and interactions with other molecules, making it a valuable subject for study.
Used in Pharmaceutical Development:
2-(1-Trityl-1H-imidazol-4-yl)-ethylamine hydrate is used as a potential pharmaceutical candidate for the development of new drugs. The presence of the imidazole ring, which is found in histidine and other biomolecules, suggests that this substance may have biological activity or could be modified to create new therapeutic agents.
Used in Material Science:
2-(1-Trityl-1H-imidazol-4-yl)-ethylamine hydrate is used as a component in the synthesis of new materials with unique properties. The trityl group and the ethylamine group may contribute to the formation of novel structures with potential applications in various industries, such as electronics or nanotechnology.
Used in Analytical Chemistry:
2-(1-Trityl-1H-imidazol-4-yl)-ethylamine hydrate is used as a reagent or a reference compound in analytical chemistry for the identification and quantification of other substances. Its distinct chemical structure may provide a specific analytical signature that can be utilized in various analytical techniques.

InChI:InChI=1/C24H23N3/c25-17-16-23-18-27(19-26-23)24(20-10-4-1-5-11-20,21-12-6-2-7-13-21)22-14-8-3-9-15-22/h1-15,18-19H,16-17,25H2

Upstream product

• 224032-26-2 N-trityl-2-(1-trityl-1H-imidazol-4-yl)ethanamine 
• 5959-80-8 2-(2-(1H-imidazol-4-yl)ethyl)isoindoline-1,3-dione 
• 76-83-5 trityl chloride 
• 195053-91-9 2-[2-(1-trityl-1H-imidazol-4-yl)ethyl]isoindoline-1,3-dione 
• 352695-71-7 4-(2-bromo-1-fluoroethyl)-1-trityl-1H-imidazole 
• 86803-29-4 4-ethenyl-1-(triphenylmethyl)-1H-imidazole 
• 50580-77-3 2,2,2-trifluoro-N-[2-(1H-imidazol-4-yl)ethyl]acetamide 
• 51-45-6 histamine 
• 312937-01-2 2,2,2-trifluoro-N-(2-(1-trityl-1H-imidazol-4-yl)ethyl)acetamide 
• 352695-85-3 4-(2-azido-1-fluoroethyl)-1-trityl-1H-imidazole 

Downstream Products

• 312937-03-4 N-(3-chloro-phenyl)-2-[2-(1-trityl-1H-imidazol-4-yl)-ethylamino]-acetamide 
• 1086277-30-6 N,N'-bis(benzyloxycarbonyl)-[2-(1-trityl-1H-imidazol-4-yl)ethyl]guanidine 
• 1109231-26-6 N-(2-(1-trityl-1H-imidazol-4-yl)ethyl)-4,5-dihydro-1H-imidazol-2-amine 
• 476494-04-9 1-[7-((Methanesulfonyl)oxy)naphthyl]-4-[2-(1-triphenylmethyl-4-imidazolyl)-ethyl]-2-piperazinone 
• 254108-76-4 methanesulfonic acid 8-(4-{2-[3-(4-bromo-3-fluoro-benzyl)-3H-imidazol-4-yl]-ethyl}-2-oxo-piperazin-1-yl)-naphthalen-2-yl ester 
• 312937-07-8 1-(3-chloro-phenyl)-4-[2-(1-trityl-1H-imidazol-4-yl)-ethyl]-piperazin-2-one 
• 405551-77-1 3-(4-chloro-phenyl)-3-pyridin-2-yl-N-[2-(1-trityl-1H-imidazol-4-yl)-ethyl]-propionamide 
• 476494-03-8 methanesulfonic acid 8-{2-[2-(1-trityl-1H-imidazol-4-yl)-ethylamino]-acetylamino}-naphthalen-2-yl ester 

Relevant academic research and scientific papers

GLP RECEPTOR AGONISTS

The disclosures herein relate to novel compounds of formula (1 ): and salts thereof, wherein Q, W, X, Y, Z, AA1, AA2, AA3, AA4, AA5, AA6, AA7, AA8, AA9, LysR, R1, R2 and n are defined herein, and their use in treating, preventing, ameliorating, controlling or reducing the risk of disorders associated with Glucagon-like peptide (GLP) receptors.

ORAL GLP RECEPTOR AGONISTS

The disclosures herein relate to novel compounds of formula (1a) or formula (1b): and salts thereof, wherein S, T, W, Z, AA1, AA2, AA3, AA4, AA5, AA6, AA7, AA8, AA9, AA10, AA11, AA12, AA13, AA14, AA15, A16, AA17, AA18, AA19, AA20, AA21, AA22, Sa, Ta, Wa, Xa, Ya, Za, AA1a, AA2a, AA3a, AA4a, AA 5a, AA 6a,AA 7a,AA8a,AA 9a,AA 10a,AA11a,AA 12a,AA13aAA 14a,AA15a,AA 16a, R, R1 and R2 are defined herein, and their use in treating, preventing, ameliorating, controlling or reducing the risk of disorders associated with Glucagon-like peptide (GLP) receptors.

UR-DEBa176: A 2,4-Diaminopyrimidine-Type Radioligand Enabling Binding Studies at the Human, Mouse, and Rat Histamine H4 Receptors

Differences in sequence homology between human (h), mouse (m), and rat (r) histamine H4 receptors (H4R) cause discrepancies regarding affinities, potencies, and/or efficacies of ligands and therefore compromise translational animal models and the applicability of radioligands. Aiming at a radioligand enabling robust and comparative binding studies at the h/m/rH4Rs, 2,4-diaminopyrimidines were synthesized and pharmacologically investigated. The most notable compounds identified were two (partial) agonists with comparable potencies at the h/m/rH4Rs: UR-DEBa148 (N-neopentyl-4-(1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)pyrimidin-2-amine bis(2,2,2-trifluoroacetate), 43), the most potent [pEC50 (reporter gene assay) = 9.9/9.6/10.3] compound in the series being slightly G-protein biased and UR-DEBa176 [(R)-4-[3-(dimethylamino)pyrrolidin-1-yl]-N-neopentylpyrimidin-2-amine bis(2,2,2-trifluoroacetate), 46, pEC50 (reporter gene assay) = 8.7/9.0/9.2], a potential "cold" form of a tritiated H4R ligand. After radiolabeling, binding studies with [3H]UR-DEBa176 ([3H]46) at the h/m/rH4Rs revealed comparable Kd values (41/17/22 nM), low nonspecific binding (11-17%, aKd), and fast associations/dissociations (25-30 min) and disclosed [3H]UR-DEBa176 as useful molecular tool to determine h/m/rH4R binding affinities for H4R ligands.

Tyrosinase and catechol oxidase activity of copper(I) complexes supported by imidazole-based ligands: structure–reactivity correlations

Four new imidazole-based ligands, 4-((1H-imidazol-4-yl)methyl)-2-phenyl-4,5-dihydrooxyzole (LOL1), 4-((1H-imidazol-4-yl)methyl)-2-(tert-butyl)-4,5-dihydrooxyzole (LOL2), 4-((1H-imidazol-4-yl)methyl)-2-methyl-4,5-dihydrooxyzole (LOL3), and N-(2,2-dimethylpropylidene)-2-(1-trityl-1H-imidazol-4-yl-)ethyl amine (Limz1), have been synthesized. The corresponding copper(I) complexes [Cu(I)(LOL1)(CH3CN)]PF6 (CuLOL1), [Cu(I)(LOL2)(CH3CN)]PF6 (CuLOL2), [Cu(I)(LOL3)(CH3CN)]PF6 (CuLOL3), [Cu(I)(Limz1)(CH3CN)2]PF6 (CuLimz1) as well as the Cu(I) complex derived from the known ligand bis(1-methylimidazol-2-yl)methane (BIMZ), [Cu(I)(BIMZ)(CH3CN)]PF6 (CuBIMZ), are screened as catalysts for the oxidation of 3,5-di-tert-butylcatechol (3,5-DTBC-H2) to 3,5-di-tert-butylquinone (3,5-DTBQ). The primary reaction product of these oxidations is 3,5-di-tert-butylsemiquinone (3,5-DTBSQ) which slowly converts to 3,5-DTBQ. Saturation kinetic studies reveal a trend of catalytic activity in the order CuLOL3?≈?CuLOL1?>?CuBIMZ?>?CuLOL2?>?CuLimz1. Additionally, the catalytic activity of the copper(I) complexes towards the oxygenation of monophenols is investigated. As substrates 2,4-di-tert-butylphenol (2,4-DTBP-H), 3-tert-butylphenol (3-TBP-H), 4-methoxyphenol (4-MeOP-H), N-acetyl-l-tyrosine ethyl ester monohydrate (NATEE) and 8-hydroxyquinoline are employed. The oxygenation products are identified and characterized with the help of UV/Vis and NMR spectroscopy, mass spectrometry, and fluorescence measurements. Whereas the copper complexes with ligands containing combinations of imidazole and imine functions or two imidazole units (CuLimz1 and CuBIMZ) are found to exhibit catalytic tyrosinase activity, the systems with ligands containing oxazoline just mediate a stoichiometric conversion. Correlations between the structures of the complexes and their reactivities are discussed.

DOUBLE-ACYLATED GLP-1 DERIVATIVES

The invention relates to a derivative of a GLP-1 analogue, which analogue comprises a first K residue at a position corresponding to position 37 of GLP-1 (7-37) (SEQ ID NO: 1), a second K residue at a position corresponding to position 26 of GLP-1 (7-37), and a maximum of ten amino acid modifications as compared to GLP-1 (7-37), wherein the first K residue is designated K37, and the second K residue is designated K26, which derivative comprises two albumin binding moieties attached to K26 and K37, respectively, wherein the albumin binding moiety comprises a protracting moiety selected from: ????????Chem. 1:?????HOOC-(CH2)x-CO-* ????????Chem. 2:?????HOOC-C6H4-O-(CH2)y-CO-* ????????Chem. 3:?????R1-C6H4-(CH2)z-CO-* ????????Chem. 4:?????HOOC-C4SH2-(CH2)w-CO-* in which x is an integer in the range of 6-18, y is an integer in the range of 3-17, z is an integer in the range of 1-5, R1 is a group having a molar mass not higher than 150 Da, and w is an integer in the range of 6-18; with the proviso that when the protracting moiety is Chem. 1, the albumin binding moiety further comprises a linker of formula Chem. 5: *-NH-(CH2)2-(O-(CH2)2)k-O-(CH2)n-CO-*, wherein k is an integer in the range of 1-5, and n is an integer in the range of 1-5; or a pharmaceutically acceptable salt, amide, or ester thereof. The invention also relates to the pharmaceutical use thereof, for example in the treatment and/or prevention of all forms of diabetes and related diseases, as well as to corresponding novel peptides and side chain intermediates. The derivatives are suitable for oral administration.

1,3 AND 1,3,5 SUBSTITUTED IMIDAZOLES AS ANTIHYPERTENSIVES

The present invention provides novel 1,5 and 1,3,5-substituted imidazole compounds of formulas (I), (IIa), (IIIb) in hydrophilic or lipophilic form, which are useful as angiotensin II AT1 receptor antagonists with sympathetic suppressant properties. In particular, the invention provides pharmaceutical compositions containing the pharmacophoric groups of Losartan and Clonidine as well compounds, processes and intermediates for preparing compounds and their use in methods of treating hypertension and cardiovascular diseases through Renin Angiotensin System (RAS) and Sympathetic System (SS). Alkylated histamine based double action Saltans are lipophilic and can act transdermally.

Acylguanidines as bioisosteres of guanidines: NG-acylated imidazolylpropylguanidines, a new class of histamine h2 receptor agonists

N1-Aryl(heteroaryl)alkyl-N2-[3-(1H-imidazol-4-yl) propyl]guanidines are potent histamine H2-receptor (H2R) agonists, but their applicability is compromised by the lack of oral bioavailability and CNS penetration. To improve pharmacokinetics, we introduced carbonyl instead of methylene adjacent to the guanidine moiety, decreasing the basicity of the novel H2R agonists by 4-5 orders of magnitude. Some acylguanidines with one phenyl ring were even more potent than their diaryl analogues. As demonstrated by HPLC-MS, the acylguanidines (bioisosteres of the alkylguanidines) were absorbed from the gut of mice and detected in brain. In GTPase assays using recombinant receptors, acylguanidines were more potent at the guinea pig than at the human H2R. At the hH1R and hH3R, the compounds were weak to moderate antagonists or partial agonists. Moreover, potent partial hH4R agonists were identified. Receptor subtype selectivity depends on the imidazolylpropylguanidine moiety (privileged structure), opening an avenue to distinct pharmacological tools including potent H4R agonists.

INHIBITORS OF PRENYL-PROTEIN TRANSFERASE

The present invention is directed to peptidomimetic piperazine-containing macrocyclic compounds which inhibit prenyl-protein transferase and the prenylation of the oncogene protein Ras. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for inhibiting prenyl-protein transferase and the prenylation of the oncogene protein Ras

Potent inhibitors of farnesyltransferase and geranylgeranyltransferase-I

Compound 1 has been shown to be a dual prenylation inhibitor with FPTase (IC50=2 nM) and GGPTase-I (IC50=95 nM). Analogues of 1, which replaced the cyanophenyl group with various biaryls, led to the discovery of highly potent dual FPTase/GGPTase-I inhibitors. 4-Trifluoromethylphenyl, trifluoropentynyl, and trifluoropentyl were identified as good p-cyano replacements.

New building blocks for fluorinated imidazole derivatives: Preparation of β-fluoro- and β,β-difluorohistamine

We demonstrate that "FBr" addition to 1-trityl-4-vinyl-1H-imidazole (7) provides a convenient route to side-chain-fluorinated histamines. Thus, addition of "FBr" to the double bond of 7 occurs with Markovnikov regioselectivity to produce 4-(2-bromo-1-fluoroethyl)-1-trityl-1H-imidazole (8). Substitution with azide, reduction, and removal of the trityl group provide β-fluorohistamine (1) as the dihydrochloride. Elimination of HBr from 8 followed by a second addition of "FBr" gives 4-(2-bromo-1,1-difluoroethyl)-1-trityl-1H-imidazole (15). This was similarly converted to β,β-difluorohistamine (2) as the dihydrochloride.